Targeted Nanoparticle Binding to Hydroxyapatite in a High Serum Environment for Early Detection of Heart Disease
Source abstract
Abstract
The impact of the protein-rich in vivo environment on targeted binding of functionalized nanoparticles has been an active field of research over the past several years. Current research aims at better understanding the nature of the protein corona and how it may be possible for targeted binding to occur even in the presence of serum. Much of the current research focuses on nanoparticles targeted to particular cell receptors or features with the aim of cellular uptake. However, similar research has not been performed on nanoparticles that are targeted to non-protein disease features, such as hydroxyapatite (HA). HA is a crystalline calcium-phosphate mineral that is present in large quantities in bone, and in smaller quantities in diseased cardiovascular tissue in cases of atherosclerosis or various stenoses. Our work aims to gain a better understanding of the behavior of PEGylated, peptide-coated superparamagnetic iron oxide nanoparticles (SPIONs) in a biologically-relevant high-protein environment (50% serum). We first determined that specific binding to HA occurs at significantly higher rates than non-specific binding in the absence of serum protein. We then examined nanoparticle interactions with serum proteins, including determination of the relative quantities of protein in the hard vs. soft protein corona. Finally, we examined specific and non-specific binding of targeted SPIONs in 50% serum, and determined that targeted binding may still occur with significant (p < 0.05) selectivity. We hypothesize that this may be because the nature of the binding interactions between the peptides and the HA are, by definition, less specific than the protein-protein interactions required for nanoparticles to bind to specific cells or cell features. These results suggest that these targeted SPIONs may be further developed for use in early detection of heart diseases such as atherosclerosis and aortic stenosis.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Protease and Inhibitor Mechanisms · Iron Metabolism and Disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering, Boston University 44 Cummington Mall, Boston, Massachusetts 02215, United States
Applied Imaging Science Laboratory, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02215, United States
Department of Biochemistry Microbiology and Immunology, Faculty of Medicine, The University of Ottawa, 501 Smyth Road, Ottowa, ON K1H 3L7 Canada
Funding
Boston University
References (91)
Show source-provided references
1. 10.1038/nbt99410.1038/nbt994 ↗
2. 10.1109/IWMPI.2015.710706710.1109/IWMPI.2015.7107067 ↗
3. 10.1073/pnas.091414010710.1073/pnas.0914140107 ↗
4. 10.2310/7290.2015.0000210.2310/7290.2015.00002 ↗
5. 10.1073/pnas.060175510310.1073/pnas.0601755103 ↗
6. 10.1021/la050345110.1021/la0503451 ↗
7. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
8. 10.1038/nrd261410.1038/nrd2614 ↗
9. 10.1016/j.tips.2009.08.00410.1016/j.tips.2009.08.004 ↗
10. 10.1021/ar200084x10.1021/ar200084x ↗
11. 10.1073/pnas.040933610210.1073/pnas.0409336102 ↗
12. 10.1016/j.jconrel.2012.04.00910.1016/j.jconrel.2012.04.009 ↗
13. 10.1016/j.biomaterials.2015.10.01910.1016/j.biomaterials.2015.10.019 ↗
14. 10.1016/j.jconrel.2011.09.09810.1016/j.jconrel.2011.09.098 ↗
15. 10.1016/S1748-0132(08)70014-810.1016/S1748-0132(08)70014-8 ↗
16. 10.1021/cr100440g10.1021/cr100440g ↗
17. 10.1073/pnas.060858210410.1073/pnas.0608582104 ↗
18. 10.1021/ja408241410.1021/ja4082414 ↗
19. 10.1021/mp200626j10.1021/mp200626j ↗
20. 10.1021/ja107583h10.1021/ja107583h ↗
21. 10.1021/ja309812z10.1021/ja309812z ↗
22. 10.1039/c3cc37307j10.1039/c3cc37307j ↗
23. 10.1038/nnano.2012.23710.1038/nnano.2012.237 ↗
24. 10.1016/j.nantod.2016.10.00510.1016/j.nantod.2016.10.005 ↗
25. 10.2147/IJN.S12930010.2147/IJN.S129300 ↗
26. 10.1021/nn901372t10.1021/nn901372t ↗
27. 10.1016/S0927-7765(99)00156-310.1016/S0927-7765(99)00156-3 ↗
28. 10.3390/ijms1305555410.3390/ijms13055554 ↗
29. 10.1021/jp971695210.1021/jp9716952 ↗
30. 10.1002/elps.20060069410.1002/elps.200600694 ↗
31. 10.1039/c3nr05559k10.1039/c3nr05559k ↗
32. 10.1021/ja208433810.1021/ja2084338 ↗
33. 10.1021/acsami.6b0509910.1021/acsami.6b05099 ↗
34. 10.1016/j.biocel.2016.01.00510.1016/j.biocel.2016.01.005 ↗
35. 10.1002/jbm.a.3078110.1002/jbm.a.30781 ↗
36. 10.1021/nl072471q10.1021/nl072471q ↗
37. 10.2214/ajr.183.6.0183181310.2214/ajr.183.6.01831813 ↗
38. 10.1016/j.atherosclerosis.2012.07.02310.1016/j.atherosclerosis.2012.07.023 ↗
39. 10.1016/S1369-7021(11)70163-810.1016/S1369-7021(11)70163-8 ↗
40. 10.1002/nbm.90310.1002/nbm.903 ↗
41. 10.1002/jmri.122410.1002/jmri.1224 ↗
42. 10.1016/j.mattod.2015.08.02210.1016/j.mattod.2015.08.022 ↗
43. 10.1002/adma.20070232210.1002/adma.200702322 ↗
44. 10.1021/jp804282u10.1021/jp804282u ↗
45. 10.1021/la204628c10.1021/la204628c ↗
46. 10.1016/j.colsurfb.2014.04.02710.1016/j.colsurfb.2014.04.027 ↗
47. 10.1021/ma971777o10.1021/ma971777o ↗
48. NanoBrook 90Plus PALS Particle Size Analyzer|Brookhaven.https://www.brookhaveninstruments.com/nanobrook-90plus (accessed Jun 25, 2018).
49. 10.1126/science.287.5460.198910.1126/science.287.5460.1989 ↗
50. 10.1007/s11051-008-9405-010.1007/s11051-008-9405-0 ↗
51. 10.1021/bc050050z10.1021/bc050050z ↗
52. 10.1002/mrm.2203710.1002/mrm.22037 ↗
53. 10.1002/mrm.2135910.1002/mrm.21359 ↗
54. 10.1118/1.214833110.1118/1.2148331 ↗
55. 10.1371/journal.pone.005676410.1371/journal.pone.0056764 ↗
56. 10.1063/1.494764710.1063/1.4947647 ↗
57. 10.1016/j.coph.2014.08.00210.1016/j.coph.2014.08.002 ↗
58. 10.2147/IJN.S3032010.2147/IJN.S30320 ↗
59. Di Marco M. · Int. J. Nanomedicine · 2007 · 2 · 609
60. 10.1016/j.addr.2006.09.01310.1016/j.addr.2006.09.013 ↗
61. 10.1515/bmt-2011-010910.1515/bmt-2011-0109 ↗
62. 10.1177/1045441100011003010110.1177/10454411000110030101 ↗
63. 10.1093/rheumatology/ken38510.1093/rheumatology/ken385 ↗
64. 10.1016/j.cytogfr.2008.08.00110.1016/j.cytogfr.2008.08.001 ↗
65. 10.1021/ja802003h10.1021/ja802003h ↗
66. 10.1021/ja203340u10.1021/ja203340u ↗
67. 10.2147/IJN.S5511810.2147/IJN.S55118 ↗
68. 10.4143/crt.2016.09110.4143/crt.2016.091 ↗
69. 10.1016/j.biomaterials.2004.05.02210.1016/j.biomaterials.2004.05.022 ↗
70. 10.1109/TNB.2003.82027710.1109/TNB.2003.820277 ↗
71. 10.1021/acs.jpcc.6b0935610.1021/acs.jpcc.6b09356 ↗
72. 10.1016/j.apcata.2017.09.03410.1016/j.apcata.2017.09.034 ↗
73. 10.1002/jmri.2119410.1002/jmri.21194 ↗
74. 10.1161/01.ATV.20.6.163010.1161/01.ATV.20.6.1630 ↗
75. 10.1007/BF0254623710.1007/BF02546237 ↗
76. 10.1161/CIRCRESAHA.113.30015510.1161/CIRCRESAHA.113.300155 ↗
77. 10.1016/j.biomaterials.2010.01.01210.1016/j.biomaterials.2010.01.012 ↗
78. 10.1016/S0021-9150(02)00018-710.1016/S0021-9150(02)00018-7 ↗
79. 10.1016/j.biocel.2015.11.00510.1016/j.biocel.2015.11.005 ↗
80. 10.1016/j.carbon.2009.01.02610.1016/j.carbon.2009.01.026 ↗
81. 10.1021/acs.langmuir.5b0416010.1021/acs.langmuir.5b04160 ↗
82. 10.1097/00004728-199107000-0001810.1097/00004728-199107000-00018 ↗
83. 10.2214/AJR.12.954310.2214/AJR.12.9543 ↗
84. 10.1073/pnas.94.16.837810.1073/pnas.94.16.8378 ↗
85. 10.1038/srep0502010.1038/srep05020 ↗
86. 10.1371/journal.pone.012900810.1371/journal.pone.0129008 ↗
87. 10.1016/j.bbamem.2015.11.01210.1016/j.bbamem.2015.11.012 ↗
88. 10.1016/j.bpj.2008.12.392910.1016/j.bpj.2008.12.3929 ↗
89. 10.1007/BF0097158210.1007/BF00971582 ↗
90. 10.1039/c2cc17852d10.1039/c2cc17852d ↗
91. 10.1016/j.xphs.2016.06.02110.1016/j.xphs.2016.06.021 ↗